Results 161 to 170 of about 1,375,377 (295)

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

open access: yesAddiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens   +7 more
wiley   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

open access: yesAddiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne   +9 more
wiley   +1 more source

Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms. [PDF]

open access: yesDrug Alcohol Depend Rep
McKee SA   +6 more
europepmc   +1 more source

Binge eating disorder

open access: yes, 2004
Binge eating disorder was first described in 1955. However, its upgrade to a diagnostic category only occurred in 1994, when it was included in appendix B of DSM IV, with provisory criteria. It is characterized by recurrent episodes of binge eating, without any compensatory behavior to prevent a possible weight gain.
Azevedo, Alexandre Pinto de   +2 more
openaire   +1 more source

Prognostic significance of prior alcohol use disorder in patients with presumed metabolic dysfunction‐associated steatotic liver disease: A large multi‐center cohort study

open access: yesAddiction, EarlyView.
Abstract Background and aims Alcohol use disorder (AUD) follows a chronic, relapsing course but is often overlooked when alcohol consumption is minimal at the time of evaluation. We aimed to assess the prognostic impact of a prior AUD diagnosis on liver‐related outcomes in patients with presumed metabolic dysfunction‐associated steatotic liver disease (
Butros Fakhoury   +6 more
wiley   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

open access: yesThe American Journal on Addictions, EarlyView.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas   +10 more
wiley   +1 more source

Implementing Supported Digital Enhanced Cognitive Behavior Therapy for Binge Eating Disorder in Routine Care: Mixed Methods Service Evaluation. [PDF]

open access: yesJ Med Internet Res
Osborne EL   +16 more
europepmc   +1 more source

Living with Binge Eating Disorder

open access: yes
Diplomsko delo se osredotoča na življenje posameznikov z izkušnjo kompulzivnega prenajedanja, motnje hranjenja, ki v javnosti pogosto ostaja spregledana.
Ratej, Lara
core  

Let's Co! The how‐to of working within a co‐production framework to devise, design and execute collaborative multisite clinical trials

open access: yesBritish Journal of Clinical Psychology, EarlyView.
Abstract Objectives To document the steps undertaken in a full collaborative co‐production design process undertaken between a group of lived experience, clinical and research collaborators to determine the selection and design of three large‐scale, multisite, clinically focused studies (including two clinical trials) targeting eating disorders.
Sarah Maguire   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy